Alumis (NASDAQ:ALMS) Insider Sanam Pangali Sells 5,000 Shares of Stock

Posted by Stanley Muller on Jul 8th, 2026

Alumis Inc. (NASDAQ:ALMS – Get Free Report) insider Sanam Pangali sold 5,000 shares of the company’s stock in a transaction on Monday, July 6th. The shares were sold at an average price of $28.00, for a total value of $140,000.00. Following the sale, the insider owned 11,111 shares of the company’s stock, valued at approximately $311,108. This trade represents a 31.03% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Alumis Trading Up 1.7%

ALMS stock traded up $0.50 during trading on Wednesday, reaching $29.77. The stock had a trading volume of 2,712,999 shares, compared to its average volume of 2,184,009. The firm has a market cap of $3.80 billion, a PE ratio of -15.04 and a beta of -0.73. The stock’s 50 day moving average is $23.37 and its two-hundred day moving average is $23.18. Alumis Inc. has a 52 week low of $3.24 and a 52 week high of $31.35.

Alumis (NASDAQ:ALMS – Get Free Report) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.01). The business had revenue of $1.74 million for the quarter, compared to analysts’ expectations of $2.10 million. Alumis had a negative net margin of 2,825.70% and a negative return on equity of 88.79%. On average, research analysts anticipate that Alumis Inc. will post -2.87 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Russell Investments Group Ltd. increased its stake in Alumis by 320.9% in the 3rd quarter. Russell Investments Group Ltd. now owns 6,419 shares of the company’s stock worth $26,000 after buying an additional 4,894 shares in the last quarter. New York State Common Retirement Fund lifted its position in shares of Alumis by 173.7% in the second quarter. New York State Common Retirement Fund now owns 11,767 shares of the company’s stock valued at $35,000 after acquiring an additional 7,467 shares in the last quarter. KBC Group NV bought a new position in shares of Alumis in the first quarter worth about $42,000. Strs Ohio raised its stake in Alumis by 300.0% during the 1st quarter. Strs Ohio now owns 2,000 shares of the company’s stock valued at $44,000 after purchasing an additional 1,500 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its holdings in Alumis by 26.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,724 shares of the company’s stock worth $46,000 after purchasing an additional 979 shares in the last quarter.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ALMS. Oppenheimer lifted their price target on shares of Alumis from $50.00 to $55.00 and gave the stock an “outperform” rating in a research note on Monday, March 30th. Wells Fargo & Company raised their target price on Alumis from $49.00 to $51.00 and gave the stock an “overweight” rating in a report on Friday, May 15th. Chardan Capital lifted their target price on Alumis from $38.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, May 19th. Morgan Stanley reissued an “overweight” rating and set a $39.00 price target on shares of Alumis in a report on Friday, May 15th. Finally, Wall Street Zen cut Alumis from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $40.30.

Get Our Latest Analysis on ALMS

Alumis Company Profile

(Get Free Report)

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.